Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Henry Schein ( (HSIC) ) just unveiled an announcement.
On January 10, 2026, Henry Schein’s board appointed Frederick M. Lowery as chief executive officer effective March 2, 2026, expanding the board from 14 to 15 members to add him as a director while long-serving CEO Stanley M. Bergman, who has led the company for 35 years, transitions to the role of non-CEO chairman to oversee a managed leadership handover. Lowery, a 54-year-old industry veteran with more than two decades of healthcare distribution and operational experience at Thermo Fisher Scientific and earlier roles at Maytag and General Motors, has been brought in to drive Henry Schein’s next phase of growth and execution of its BOLD+1 strategy, supported by a substantial employment package, inclusion in an expanded executive severance plan, and by-law changes that formally separate the CEO role from the positions of president and chairman—moves that together signal a deliberate modernization of the company’s governance and leadership structure with potential implications for shareholder value and strategic execution.
The most recent analyst rating on (HSIC) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.
Spark’s Take on HSIC Stock
According to Spark, TipRanks’ AI Analyst, HSIC is a Outperform.
The score is driven primarily by steady financial performance with some margin/leverage and cash-conversion constraints, reinforced by strong technical momentum. Valuation is less supportive due to a higher P/E and no dividend, while the latest earnings call added positives through improved margins, strategic execution, and constructive EPS guidance.
To see Spark’s full report on HSIC stock, click here.
More about Henry Schein
Henry Schein, Inc., listed on Nasdaq as HSIC, is the world’s largest provider of healthcare solutions to office-based dental and medical professionals, with a business model that combines healthcare distribution with owned product lines spanning manufacturing, R&D, marketing, and sales. The company focuses on supporting dental and medical practitioners globally through an integrated portfolio of products, logistics, and technology-enabled services, and is currently executing its BOLD+1 strategic growth plan in partnership with private equity firm KKR.
Average Trading Volume: 1,400,040
Technical Sentiment Signal: Buy
Current Market Cap: $9.3B
Find detailed analytics on HSIC stock on TipRanks’ Stock Analysis page.